Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation

What are the impacts of obesity and diabetes on the effectiveness and safety of early rhythm control in patients with early atrial fibrillation and cardiovascular conditions?In this prespecified secondary analysis of the EAST-AFNET 4 randomized clinical trial involving 1086 patients with obesity and 1690 without, obesity did not change the effect of early rhythm control therapy. In 694 patients with diabetes, there was no interaction with the treatment effect of early rhythm control.Early rhythm control therapy retains its effectiveness and safety in patients with and without diabetes and in patients with and without obesity.

Corresponding Author: Paulus Kirchhof, MD, Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20251 Hamburg, Germany (p.kirchhof@uke.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.